Literature DB >> 19734454

Post-translational Regulation of Runx2 in Bone and Cartilage.

J H Jonason1, G Xiao, M Zhang, L Xing, D Chen.   

Abstract

The Runx2 gene product is essential for mammalian bone development. In humans, Runx2 haploinsufficiency results in cleidocranial dysplasia, a skeletal disorder characterized by bone and dental abnormalities. At the molecular level, Runx2 acts as a transcription factor for genes expressed in hypertrophic chondrocytes and osteoblasts. Runx2 gene expression and protein function are regulated on multiple levels, including transcription, translation, and post-translational modification. Furthermore, Runx2 is involved in numerous protein-protein interactions, most of which either activate or repress transcription of target genes. In this review, we discuss expression of Runx2 during development as well as the post-translational regulation of Runx2 through modification by phosphorylation, ubiquitination, and acetylation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19734454      PMCID: PMC2883617          DOI: 10.1177/0022034509341629

Source DB:  PubMed          Journal:  J Dent Res        ISSN: 0022-0345            Impact factor:   6.116


  122 in total

1.  The protein kinase C pathway plays a central role in the fibroblast growth factor-stimulated expression and transactivation activity of Runx2.

Authors:  Hyun-Jung Kim; Jung-Hwan Kim; Suk-Chul Bae; Je-Yong Choi; Hyun-Jung Kim; Hyun-Mo Ryoo
Journal:  J Biol Chem       Date:  2002-10-25       Impact factor: 5.157

2.  E3 ubiquitin ligase Smurf1 mediates core-binding factor alpha1/Runx2 degradation and plays a specific role in osteoblast differentiation.

Authors:  Ming Zhao; Mei Qiao; Babatunde O Oyajobi; Gregory R Mundy; Di Chen
Journal:  J Biol Chem       Date:  2003-05-07       Impact factor: 5.157

3.  Functional analysis of RUNX2 mutations in cleidocranial dysplasia: novel insights into genotype-phenotype correlations.

Authors:  Taketoshi Yoshida; Hirokazu Kanegane; Motomi Osato; Masatoshi Yanagida; Toshio Miyawaki; Yoshiaki Ito; Katsuya Shigesada
Journal:  Blood Cells Mol Dis       Date:  2003 Mar-Apr       Impact factor: 3.039

4.  IRES-dependent translational control of Cbfa1/Runx2 expression.

Authors:  Zhou-Sheng Xiao; Leigh G Simpson; L Darryl Quarles
Journal:  J Cell Biochem       Date:  2003-02-15       Impact factor: 4.429

5.  Hedgehog signaling enhances core-binding factor a1 and receptor activator of nuclear factor-kappaB ligand (RANKL) gene expression in chondrocytes.

Authors:  M Takamoto; K Tsuji; T Yamashita; H Sasaki; T Yano; Y Taketani; T Komori; A Nifuji; M Noda
Journal:  J Endocrinol       Date:  2003-06       Impact factor: 4.286

6.  Regulation of the bone-specific osteocalcin gene by p300 requires Runx2/Cbfa1 and the vitamin D3 receptor but not p300 intrinsic histone acetyltransferase activity.

Authors:  Jose Sierra; Alejandro Villagra; Roberto Paredes; Fernando Cruzat; Soraya Gutierrez; Amjad Javed; Gloria Arriagada; Juan Olate; Maria Imschenetzky; Andre J Van Wijnen; Jane B Lian; Gary S Stein; Janet L Stein; Martin Montecino
Journal:  Mol Cell Biol       Date:  2003-05       Impact factor: 4.272

7.  Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.

Authors:  Hirayuki Enomoto; Satoko Shiojiri; Kazuto Hoshi; Tatsuya Furuichi; Ryo Fukuyama; Carolina A Yoshida; Naoko Kanatani; Reiko Nakamura; Atsuko Mizuno; Akira Zanma; Kazuki Yano; Hisataka Yasuda; Kanji Higashio; Kenji Takada; Toshihisa Komori
Journal:  J Biol Chem       Date:  2003-04-15       Impact factor: 5.157

8.  Changes in Runx2/Cbfa1 expression and activity during osteoblastic differentiation of human bone marrow stromal cells.

Authors:  Chaoxiang Shui; Thomas C Spelsberg; B Lawrence Riggs; Sundeep Khosla
Journal:  J Bone Miner Res       Date:  2003-02       Impact factor: 6.741

9.  Runx2 (Cbfa1, AML-3) interacts with histone deacetylase 6 and represses the p21(CIP1/WAF1) promoter.

Authors:  Jennifer J Westendorf; S Kaleem Zaidi; Jonathan E Cascino; Rachel Kahler; André J van Wijnen; Jane B Lian; Minoru Yoshida; Gary S Stein; Xiaodong Li
Journal:  Mol Cell Biol       Date:  2002-11       Impact factor: 4.272

10.  Proteasomal degradation of Runx2 shortens parathyroid hormone-induced anti-apoptotic signaling in osteoblasts. A putative explanation for why intermittent administration is needed for bone anabolism.

Authors:  Teresita Bellido; A Afshan Ali; Lilian I Plotkin; Qiang Fu; Igor Gubrij; Paula K Roberson; Robert S Weinstein; Charles A O'Brien; Stavros C Manolagas; Robert L Jilka
Journal:  J Biol Chem       Date:  2003-10-01       Impact factor: 5.157

View more
  56 in total

1.  Role of Runx2 in IGF-1Rβ/Akt- and AMPK/Erk-dependent growth, survival and sensitivity towards metformin in breast cancer bone metastasis.

Authors:  M Tandon; Z Chen; A H Othman; J Pratap
Journal:  Oncogene       Date:  2016-01-25       Impact factor: 9.867

2.  Wip1 promotes RUNX2-dependent apoptosis in p53-negative tumors and protects normal tissues during treatment with anticancer agents.

Authors:  Anastasia R Goloudina; Kan Tanoue; Arlette Hammann; Eric Fourmaux; Xavier Le Guezennec; Dmitry V Bulavin; Sharlyn J Mazur; Ettore Appella; Carmen Garrido; Oleg N Demidov
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

3.  FOXO1 modulates osteoblast differentiation.

Authors:  Michelle F Siqueira; Stephen Flowers; Rupa Bhattacharya; Dan Faibish; Yugal Behl; Darrell N Kotton; Lou Gerstenfeld; Elizabeth Moran; Dana T Graves
Journal:  Bone       Date:  2011-01-28       Impact factor: 4.398

4.  Plant homeodomain finger protein 2 promotes bone formation by demethylating and activating Runx2 for osteoblast differentiation.

Authors:  Hye-Jin Kim; Jong-Wan Park; Kyoung-Hwa Lee; Haejin Yoon; Dong Hoon Shin; Uk-Il Ju; Seung Hyeok Seok; Seung Hyeon Lim; Zang Hee Lee; Hong-Hee Kim; Yang-Sook Chun
Journal:  Cell Res       Date:  2014-09-26       Impact factor: 25.617

5.  The RUNX2 cistrome in osteoblasts: characterization, down-regulation following differentiation, and relationship to gene expression.

Authors:  Mark B Meyer; Nancy A Benkusky; J Wesley Pike
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

Review 6.  Osteoarthritis pathogenesis: a review of molecular mechanisms.

Authors:  Bingjiang Xia; Jushi Zhang; Songfeng Hu; Hongting Jin; Peijian Tong
Journal:  Calcif Tissue Int       Date:  2014-10-14       Impact factor: 4.333

7.  Chondrocyte-Specific RUNX2 Overexpression Accelerates Post-traumatic Osteoarthritis Progression in Adult Mice.

Authors:  Sarah E Catheline; Donna Hoak; Martin Chang; John P Ketz; Matthew J Hilton; Michael J Zuscik; Jennifer H Jonason
Journal:  J Bone Miner Res       Date:  2019-06-12       Impact factor: 6.741

8.  KDM6A promotes chondrogenic differentiation of periodontal ligament stem cells by demethylation of SOX9.

Authors:  Pingting Wang; Yanjing Li; Tingting Meng; Junjiang Zhang; Yuanyuan Wei; Zhaosong Meng; Yunfeng Lin; Dayong Liu; Lei Sui
Journal:  Cell Prolif       Date:  2017-11-23       Impact factor: 6.831

9.  Oncogenic cooperation between PI3K/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells.

Authors:  Sandhya Pande; Gillian Browne; Srivatsan Padmanabhan; Sayyed K Zaidi; Jane B Lian; Andre J van Wijnen; Janet L Stein; Gary S Stein
Journal:  J Cell Physiol       Date:  2013-08       Impact factor: 6.384

10.  The effect of mesoporous bioglass on osteogenesis and adipogenesis of osteoporotic BMSCs.

Authors:  Tao Wu; Ning Cheng; Chun Xu; Wei Sun; Chengzhong Yu; Bin Shi
Journal:  J Biomed Mater Res A       Date:  2016-08-05       Impact factor: 4.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.